

Benjamin Besse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/43471/publications.pdf>

Version: 2024-02-01

370
papers

27,050
citations

13068

68
h-index

6979

154
g-index

387
all docs

387
docs citations

387
times ranked

26702
citing authors

#	ARTICLE	IF	CITATIONS
1	PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. <i>Clinical Lung Cancer</i> , 2022, 23, e243-e246.	1.1	20
2	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. <i>Journal of Thoracic Oncology</i> , 2022, 17, 103-115.	0.5	89
3	PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. <i>Clinical Lung Cancer</i> , 2022, 23, e252-e256.	1.1	10
4	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 75-90.	12.5	111
5	Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. <i>European Journal of Cancer</i> , 2022, 162, 118-127.	1.3	6
6	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 719-728.	0.8	37
7	Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. <i>Journal of Thoracic Oncology</i> , 2022, 17, 568-577.	0.5	7
8	Monitoring tumor growth rate to predict immune checkpoint inhibitorsâ€™™ treatment outcome in advanced NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	2
9	Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	15.2	225
10	MARIPOSA: phase 3 study of first-line amivantamab+â€“azertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 639-647.	1.1	44
11	Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. , 2022, 10, e004374.		13
12	Lorlatinib for advanced anaplastic lymphoma kinaseâ€“positive nonâ€“small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. <i>European Journal of Cancer</i> , 2022, 166, 51-59.	1.3	14
13	Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. <i>Cancers</i> , 2022, 14, 92.	1.7	3
14	The use of immunotherapy in older patients with advanced non-small cell lung cancer. <i>Cancer Treatment Reviews</i> , 2022, 106, 102394.	3.4	16
15	Targeting genome integrity dysfunctions impedes metastatic potency in non-small-cell lung cancer circulating tumor cell-derived eXplants. <i>JCI Insight</i> , 2022, , .	2.3	5
16	Clinical utility and outcomes impact of crystal digital PCR of sensitizing and resistance EGFR mutations in patients with advanced non-small cell lung cancer. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	0
17	Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies. , 2022, 10, e003890.		37
18	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	7

#	ARTICLE	IF	CITATIONS
19	Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. <i>Lung Cancer</i> , 2022, 169, 94-101.	0.9	6
20	Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIRO2-LUNG trial and association with intracranial outcome. <i>Lung Cancer</i> , 2022, 169, 31-39.	0.9	2
21	Prevalence of incidental pathogenic germline variants detected in cfDNA in patients with oncogene-driven non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10569-10569.	0.8	1
22	18F-FDG PET-derived parameter total lesion glycolysis (TLG) as a tool to stratify patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9062-9062.	0.8	1
23	AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with <i>RET</i> fusion-positive advanced/metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9159-TPS9159.	0.8	0
24	CtDNA shed as a tool to select immune checkpoint inhibitors (ICPI) with or without chemotherapy for patients (pts) with advanced non-small cell lung cancer (aNSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9045-9045.	0.8	3
25	Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9008-9008.	0.8	24
26	EORTC-1416-LCG/ETOP 8-15 PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8512-8512.	0.8	14
27	Lenvatinib for the treatment of thymic epithelial tumors (TETs): A real-life multicenter experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8585-8585.	0.8	1
28	Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3016-3016.	0.8	1
29	Immunosenescence, inflammaging, and cancer immunotherapy efficacy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 915-926.	1.1	12
30	Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e54-e56.	1.1	3
31	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy—Reply. <i>JAMA Oncology</i> , 2021, 7, 137.	3.4	2
32	Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. <i>Clinical Lung Cancer</i> , 2021, 22, e215-e219.	1.1	6
33	Impact of expert pathologic review of thymic epithelial tumours on diagnosis and management in a real-life setting: A RYTHMIC study. <i>European Journal of Cancer</i> , 2021, 143, 158-167.	1.3	10
34	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	3.2	76
35	Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 741-746.	1.4	9
36	Meningeal Lazarus Response to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib. <i>Cancer Management and Research</i> , 2021, Volume 13, 2805-2810.	0.9	5

#	ARTICLE	IF	CITATIONS
37	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non- <i>small cell lung cancer</i> treated with immunotherapy. <i>European Journal of Cancer</i> , 2021, 145, 221-229.	1.3	42
38	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	1.3	8
39	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. <i>Lung Cancer</i> , 2021, 155, 114-119.	0.9	12
40	Updated overall efficacy and safety of selpercatinib in patients (pts) with <i>RET</i> fusion+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9065-9065.	0.8	13
41	LincRNA-p21 as predictive response marker for preoperative chemoradiotherapy in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15534-e15534.	0.8	0
42	Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8575-8575.	0.8	2
43	Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8526-8526.	0.8	1
44	Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8578-8578.	0.8	1
45	Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301-SAFIRO2-LUNG intergroup trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9095-9095.	0.8	0
46	Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9015-9015.	0.8	8
47	Response to selpercatinib versus prior systemic therapy in patients (pts) with <i>RET</i> fusion+ non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9032-9032.	0.8	1
48	Overall survival and exploratory subgroup analyses from the phase 2 CodeBreak 100 trial evaluating sotorasib in pretreated <i>KRAS</i> p.G12C mutated non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9003-9003.	0.8	18
49	Intestinal <i>Akkermansia muciniphila</i> predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9019-9019.	0.8	5
50	Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non- <i>Small-Cell Lung Cancer</i> and High PD-L1 Expression. <i>Clinical Lung Cancer</i> , 2021, , .	1.1	0
51	Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?. <i>Translational Lung Cancer Research</i> , 2021, 10, 2868-2875.	1.3	1
52	Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation. <i>New England Journal of Medicine</i> , 2021, 384, 2371-2381.	13.9	833
53	Natural Language Processing for Patient Selection in Phase I or II Oncology Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 709-718.	1.0	5
54	Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2937-2954.	1.3	19

#	ARTICLE	IF	CITATIONS
55	Narrative review of immunotherapy in thymic malignancies. <i>Translational Lung Cancer Research</i> , 2021, 10, 3001-3013.	1.3	4
56	Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4160-4167.	3.2	64
57	Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3014-3028.	1.3	9
58	Immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2865-2867.	1.3	0
59	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	1.3	24
60	Pralsetinib for <i>RET</i> fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	5.1	222
61	Abstract 448: High prevalence of pathogenic germline variants in patients with oncogene-driven non-small cell lung cancer. <i>Cancer Research</i> , 2021, 81, 448-448.	0.4	3
62	Circulating tumor cell copy-number heterogeneity in <i>ALK</i> -rearranged non-small-cell lung cancer resistant to <i>ALK</i> inhibitors. <i>Npj Precision Oncology</i> , 2021, 5, 67.	2.3	17
63	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	1.7	5
64	Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2321-2323.	0.8	9
65	Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, 13, 1176. <i>Cancers</i> , 2021, 13, 3624.	1.7	2
66	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1039-1041.	7.7	2
67	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of <i>PD-L1</i> expression. <i>Nature Cancer</i> , 2021, 2, 794-802.	5.7	173
68	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with <i>PD-L1</i> expression $\geq 50\%$. <i>Future Oncology</i> , 2021, 17, 3007-3016.	1.1	6
69	Integrin- α V-mediated activation of <i>TGF-β2</i> regulates anti-tumour CD8 T cell immunity and response to <i>PD-1</i> blockade. <i>Nature Communications</i> , 2021, 12, 5209.	5.8	30
70	Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. <i>JCO Oncology Practice</i> , 2021, 17, e1311-e1317.	1.4	4
71	Late phase 1 studies: concepts and outcomes. <i>Lancet Oncology</i> , The, 2021, 22, e446-e455.	5.1	2
72	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. <i>European Journal of Cancer</i> , 2021, 157, 383-390.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. Radiotherapy and Oncology, 2021, 154, 125-127.	0.3	7
74	The efficacy of immune checkpoint inhibitors in thoracic malignancies. European Respiratory Review, 2021, 30, 200387.	3.0	5
75	Adjuvant immunotherapy for NSCLC – does treating earlier mean treating better?. Nature Reviews Clinical Oncology, 2021, , .	12.5	1
76	New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma. Cancer Discovery, 2021, 11, 2674-2676.	7.7	5
77	Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313.	2.2	15
78	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 102.	2.3	11
79	Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter?. Lung Cancer, 2020, 139, 216-218.	0.9	5
80	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. Clinical Cancer Research, 2020, 26, 242-255.	3.2	114
81	Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. Autoimmunity Reviews, 2020, 19, 102464.	2.5	5
82	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. Journal of Thoracic Oncology, 2020, 15, 383-391.	0.5	58
83	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. British Journal of Cancer, 2020, 122, 340-347.	2.9	24
84	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. Clinical Cancer Research, 2020, 26, 787-792.	3.2	44
85	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1147-1157.	3.3	103
86	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). Cancers, 2020, 12, 2827.	1.7	35
87	EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treatment Reviews, 2020, 90, 102105.	3.4	80
88	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. JCO Precision Oncology, 2020, 4, 829-840.	1.5	25
89	CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. Cell Reports Medicine, 2020, 1, 100127.	3.3	70
90	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. Cancers, 2020, 12, 3625.	1.7	27

#	ARTICLE	IF	CITATIONS
91	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. <i>Nature Cancer</i> , 2020, 1, 965-975.	5.7	98
92	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	2.3	16
93	Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	13.9	505
94	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i> -Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	3.2	23
95	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3758.	1.7	4
96	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	0.6	10
97	Cystic brain metastases and <i>RET</i> fusion in lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 424-425.	1.3	2
98	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5068-5077.	3.2	34
99	Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151522.	0.6	14
100	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	1.3	53
101	Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. <i>PLoS ONE</i> , 2020, 15, e0234302.	1.1	13
102	A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer. <i>ERJ Open Research</i> , 2020, 6, 00174-2019.	1.1	3
103	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	3.4	70
104	Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 144, 10-19.	0.9	14
105	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100023.	0.6	11
106	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	1.3	37
107	Immunotherapy discontinuation – how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
108	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	0.5	29

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 63-69.	0.9	12
110	Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. <i>European Journal of Cancer</i> , 2020, 131, 27-36.	1.3	44
111	Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. <i>European Radiology</i> , 2020, 30, 5021-5028.	2.3	10
112	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	1.5	36
113	18F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data. <i>EJNMMI Research</i> , 2020, 10, 88.	1.1	7
114	ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases. <i>European Oncology and Haematology</i> , 2020, 16, 18.	0.0	3
115	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2019, 11, 1149-1160.	1.0	9
116	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1400-1407.	0.5	23
117	Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e215-e216.	0.5	6
118	Letter to the Editor about Sorich et al.. <i>Journal of Thoracic Oncology</i> , 2019, 14, e209.	0.5	5
119	Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1691-1701.	5.1	233
120	In Response to the Letter by Dr. Yang et al., Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of Steroids. <i>Journal of Thoracic Oncology</i> , 2019, 14, e260-e261.	0.5	0
121	Definition of Synchronous Oligometastatic Non-small Cell Lung Cancer: A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
122	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
123	Treatment duration of checkpoint inhibitors for NSCLC. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 835-837.	5.2	6
124	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6671-6682.	3.2	95
125	Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1828-1838.	0.5	50
126	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019, 136, 145-147.	0.9	17

#	ARTICLE	IF	CITATIONS
127	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
128	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 116, 182-189.	1.3	36
129	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019, 114, 128-136.	1.3	8
130	Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 963-967.	0.5	16
131	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1230-1239.	0.9	2
132	Exploring the optimal use of alectinib. <i>Lancet Respiratory Medicine</i> , 2019, 7, 373-374.	5.2	2
133	Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	31
134	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.3	14
135	Hyperprogression—Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer? In Reply. <i>JAMA Oncology</i> , 2019, 5, 744.	3.4	6
136	Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 982-1000.	4.2	173
137	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1244-1254.	0.5	178
138	<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1370-1379.	0.8	282
139	Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?. <i>European Journal of Cancer</i> , 2019, 113, 28-31.	1.3	31
140	Pseudoprogession in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 328-331.	0.5	31
141	Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1701-1703.	0.5	6
142	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , 2019, 36, 579-581.	7.7	11
143	Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. <i>Biomarker Research</i> , 2019, 7, 28.	2.8	22
144	CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?. <i>Translational Lung Cancer Research</i> , 2019, 8, S464-S467.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 108, 120-128.	1.3	50
146	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 106, 144-159.	1.3	164
147	PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 1211-1228.	3.9	222
148	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	1.3	69
149	Should surgery be part of the multimodality treatment for stage IIIb non-small cell lung cancer?. <i>Journal of Surgical Oncology</i> , 2018, 117, 1570-1574.	0.8	3
150	Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i> advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018, 4, 00058-2017.	1.1	8
151	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	0.5	62
152	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 301-322.	0.5	43
153	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018, 91, 21-29.	1.3	222
154	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	3.4	599
155	Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 14-21.	0.9	21
156	Clinical and Translational Implications of RET Rearrangements in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 27-45.	0.5	156
157	Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1742-1745.	0.6	6
158	<i>EGFR</i> C797S, <i>EGFR</i> T790M and <i>EGFR</i> sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. <i>Oncotarget</i> , 2018, 9, 37393-37406.	0.8	34
159	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	0.8	747
160	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	1.3	66
161	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
162	Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid <i>EGFR</i> / <i>KRAS</i> analysis in 43 cases. <i>Journal of Thoracic Disease</i> , 2018, 10, 4653-4658.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1654-1667.	5.1	587
164	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018, 9, 5097.	5.8	21
165	Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. <i>European Respiratory Journal</i> , 2018, 52, 1801220.	3.1	40
166	Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1595-1601.	0.5	137
167	Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1762-1770.	0.5	60
168	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	12.5	304
169	Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer. <i>PLoS ONE</i> , 2018, 13, e0204490.	1.1	24
170	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
171	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. <i>Cancer Treatment Reviews</i> , 2018, 68, 69-79.	3.4	51
172	Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 88.	1.3	57
173	New windows open for immunotherapy in lung cancer. <i>Nature</i> , 2018, 558, 376-377.	13.7	38
174	Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1265-1271.	1.0	5
175	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 694-708.	12.5	255
176	Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, e215-e217.	0.5	12
177	Abstract 2597: Development and characterization of novel non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs)-derived xenograft (CDX) models. , 2018, , .		1
178	Abstract CT044: Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations. , 2018, , .		6
179	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	0.8	87
180	Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3080-3080.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.. Journal of Clinical Oncology, 2018, 36, 8519-8519.	0.8	20
182	Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.. Journal of Clinical Oncology, 2018, 36, 8570-8570.	0.8	11
183	Lorlatinib in patients (Pts) with previously treated ALK⁺ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.. Journal of Clinical Oncology, 2018, 36, 9032-9032.	0.8	13
184	An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2018, 36, 9095-9095.	0.8	1
185	Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.. Journal of Clinical Oncology, 2018, 36, 9097-9097.	0.8	5
186	Neutrophil-lymphocyte-ratio to complement the prediction ability of PD-L1 expression for outcomes in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.. Journal of Clinical Oncology, 2018, 36, e15102-e15102.	0.8	3
187	An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. Journal of Clinical Oncology, 2018, 36, TPS3120-TPS3120.	0.8	6
188	Abstract 3654: Identification of resistance mutations to crizotinib through circulating tumor cell (CTC) analysis inALK-rearranged non-small-cell lung cancer (NSCLC). , 2018, , .		0
189	Abstract 2147: Development of preclinical models to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies. , 2018, , .		1
190	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. Blood, 2018, 132, 2412-2412.	0.6	0
191	Diagnostic yield of a biopsy performed immediately after lung radiofrequency ablation. European Radiology, 2017, 27, 1211-1217.	2.3	18
192	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. Cancer Treatment Reviews, 2017, 55, 83-95.	3.4	58
193	MA04.02 Neratinib ± Temeolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study. Journal of Thoracic Oncology, 2017, 12, S358-S359.	0.5	42
194	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. Journal of Thoracic Oncology, 2017, 12, 963-973.	0.5	56
195	EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Pathology Research and Practice, 2017, 213, 793-798.	1.0	18
196	Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-“Small Cell Lung Cancer Patients. Cancer Research, 2017, 77, 2222-2230.	0.4	64
197	Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. Supportive Care in Cancer, 2017, 25, 3365-3373.	1.0	13
198	Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Annals of the Rheumatic Diseases, 2017, 76, 1747-1750.	0.5	200

#	ARTICLE	IF	CITATIONS
199	A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 615-625.e8.	1.1	22
200	P2.06-024 Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE-1. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1085-S1086.	0.5	1
201	P3.02c-065 Neutrophil-To-Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1315-S1316.	0.5	3
202	P3.02c-066 HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1316.	0.5	0
203	OA09.02 Should Surgery Be Part of the Multimodality Treatment for Stage III B Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S276-S277.	0.5	0
204	OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, S284-S285.	0.5	3
205	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	2.3	65
206	Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. <i>Lung Cancer</i> , 2017, 108, 72-74.	0.9	28
207	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR -mutant NSCLC Patients. EORTC 1613. <i>Clinical Lung Cancer</i> , 2017, 18, 583-588.	1.1	84
208	A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 86, 186-196.	1.3	28
209	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	5.1	535
210	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. <i>European Journal of Cancer</i> , 2017, 85, 155-157.	1.3	6
211	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1307-1316.	5.1	889
212	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017, 60, 60-68.	3.4	125
213	Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapy. <i>Lung Cancer</i> , 2017, 111, 59-60.	0.9	1
214	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 97-104.	1.1	37
215	Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1715-1722.	0.5	25
216	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2017, 112, 10-15.	0.9	3

#	ARTICLE	IF	CITATIONS
217	LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. <i>Lung Cancer</i> , 2017, 112, 62-68.	0.9	92
218	EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. <i>European Respiratory Journal</i> , 2017, 50, 1700514.	3.1	20
219	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , 2017, 77, 557-565.	0.4	10
220	Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2017, 12, e1-e3.	0.5	4
221	Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0183319.	1.1	26
222	Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017, 8, 21903-21917.	0.8	140
223	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. <i>Journal of Clinical Oncology</i> , 2017, 35, 1403-1410.	0.8	277
224	Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 11540-11540.	0.8	9
225	Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors. <i>Journal of Clinical Oncology</i> , 2017, 35, 3015-3015.	0.8	11
226	Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study. <i>Journal of Clinical Oncology</i> , 2017, 35, 9006-9006.	0.8	20
227	Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers. <i>Journal of Clinical Oncology</i> , 2017, 35, 9069-9069.	0.8	7
228	Updated survival of patients (pts) with previously treated BRAF V600E mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. <i>Journal of Clinical Oncology</i> , 2017, 35, 9075-9075.	0.8	37
229	Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Clinical Oncology</i> , 2017, 35, 9089-9089.	0.8	3
230	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 25189-25199.	0.8	12
231	Evaluation of liquid biopsies for molecular profiling in patients with advanced non-small cell lung cancer (NSCLC) in the relapse treatment setting. <i>Journal of Clinical Oncology</i> , 2017, 35, 11532-11532.	0.8	0
232	Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al. <i>Journal of Thoracic Disease</i> , 2016, 8, 2997-3002.	0.6	5
233	Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer. <i>Tumori</i> , 2016, 102, S46-S49.	0.6	7
234	Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. <i>Clinical Cancer Research</i> , 2016, 22, 5983-5991.	3.2	124

#	ARTICLE	IF	CITATIONS
235	MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2016, 17, 323-333.	0.8	7
236	Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France. <i>Journal of Thoracic Oncology</i> , 2016, 11, 391-399.	0.5	11
237	<i>KRAS</i> oncogene in lung cancer: focus on molecularly driven clinical trials. <i>European Respiratory Review</i> , 2016, 25, 71-76.	3.0	72
238	Whole brain radiotherapy in patients with NSCLC and brain metastases. <i>Lancet</i> , The, 2016, 388, 1960-1962.	6.3	15
239	Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 483.	1.1	31
240	Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. <i>ESMO Open</i> , 2016, 1, e000081.	2.0	6
241	Method for semi-automated microscopy of filtration-enriched circulating tumor cells. <i>BMC Cancer</i> , 2016, 16, 477.	1.1	29
242	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 984-993.	5.1	689
243	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1819-1836.	0.5	31
244	Liquid biopsies could be superior to tumor biopsy to provide a molecular profile in non-small cell lung cancer (NSCLC) patients. <i>Journal of Thoracic Oncology</i> , 2016, 11, S37.	0.5	0
245	Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. <i>Lung Cancer</i> , 2016, 97, 99-104.	0.9	56
246	The 5000% case: a glimpse into the financial issue of lung cancer treatment. <i>European Respiratory Journal</i> , 2016, 47, 1331-1333.	3.1	2
247	Disseminated intravascular coagulation following administration of sunitinib. <i>Molecular and Clinical Oncology</i> , 2016, 5, 121-123.	0.4	1
248	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). <i>Lancet</i> , The, 2016, 387, 1415-1426.	6.3	790
249	The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2016, 17, 161-168.	1.1	13
250	A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib. <i>Investigational New Drugs</i> , 2016, 34, 397-398.	1.2	22
251	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 366-373.	3.2	20
252	Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. <i>Oncolmmunology</i> , 2016, 5, e1071008.	2.1	545

#	ARTICLE	IF	CITATIONS
253	Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples. <i>Cancer Research</i> , 2016, 76, 3192-3192.	0.4	3
254	An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E mutant advanced non-small cell lung cancer (NSCLC); Tj ETQq0 0 0 rgBT /08erlock 50 Tf 50 69	0.8	0
255	Radiogenomics in 332 metastatic non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11563-11563.	0.8	2
256	Pathological central review of 290 thymic epithelial tumors (TET): The national network RYTHMIC experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8568-8568.	0.8	4
257	Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9005-9005.	0.8	17
258	Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9009-9009.	0.8	53
259	Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9014-9014.	0.8	8
260	Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9034-9034.	0.8	11
261	Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9059-9059.	0.8	2
262	Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9066-9066.	0.8	9
263	A phase II multicenter, randomized, placebo-controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9107-TPS9107.	0.8	1
264	Novel mutations in sporadic typical carcinoids of the lung (lung-TC): Tumor genomic profile by next generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11596-11596.	0.8	0
265	Evaluation of liquid biopsies for molecular profiling and monitoring in non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11533-11533.	0.8	0
266	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8571-TPS8571.	0.8	7
267	ALK-amplified circulating tumor cells as a surrogate marker for crizotinib benefit in ALK-rearranged non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11515-11515.	0.8	0
268	Differential epithelial and mesenchymal CTC profiling according to non-small cell lung cancer (NSCLC) molecular subtype.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23093-e23093.	0.8	0
269	Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance. , 2016, , .		1
270	Abstract 2254: Variations in the epithelial-mesenchymal transition (EMT) program by non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs) do not influence survival. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
271	Abstract 856: Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib. , 2016, , .		0
272	Abstract 2256: Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer. , 2016, , .		0
273	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. Journal of Thoracic Oncology, 2015, 10, 1451-1457.	0.5	141
274	A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, e44-e45.	0.5	1
275	Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-“Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2015, 10, e72-e73.	0.5	5
276	Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. Cancer Biomarkers, 2015, 15, 151-156.	0.8	12
277	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2015, 15, 1605-1629.	1.5	25
278	Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?. European Respiratory Journal, 2015, 46, 1548-1550.	3.1	3
279	Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. Pathology Research and Practice, 2015, 211, 996-1002.	1.0	13
280	Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. European Respiratory Review, 2015, 24, 582-593.	3.0	22
281	Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Targeted Oncology, 2015, 10, 247-253.	1.7	54
282	Bevacizumab in Patients with Nonsquamous Non-“Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clinical Cancer Research, 2015, 21, 1896-1903.	3.2	199
283	Crizotinib Therapy for Advanced Lung Adenocarcinoma and a <i>ROS1</i> Rearrangement: Results From the EUROS1 Cohort. Journal of Clinical Oncology, 2015, 33, 992-999.	0.8	326
284	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	0.6	308
285	Therapeutic management of ALK+nonsmall cell lung cancer patients. European Respiratory Journal, 2015, 46, 230-242.	3.1	21
286	CD8+CD103+ Tumor-“Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. Journal of Immunology, 2015, 194, 3475-3486.	0.4	477
287	Lung cancer in never-smokers. European Respiratory Journal, 2015, 45, 1214-1217.	3.1	35
288	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics, 2015, 47, 1200-1205.	9.4	252

#	ARTICLE	IF	CITATIONS
289	Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.. Journal of Clinical Oncology, 2015, 33, TPS2620-TPS2620.	0.8	5
290	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152.	0.8	22
291	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study.. Journal of Clinical Oncology, 2015, 33, 11076-11076.	0.8	0
292	Abstract 1548: Baseline serum levels of osteopontin and thrombospondin-1 predict shorter overall survival in primary resected non-small cell lung cancer. , 2015, , .		0
293	Methodology of clinical trials in lung cancer. Chinese Clinical Oncology, 2015, 4, 44.	0.4	1
294	Is sacrificing the phrenic nerve during thymoma resection worthwhile?. European Journal of Cardio-thoracic Surgery, 2014, 45, e151-e155.	0.6	27
295	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. European Respiratory Review, 2014, 23, 367-378.	3.0	78
296	Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer. Future Oncology, 2014, 10, 823-833.	1.1	12
297	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	0.6	210
298	Challenges and controversies in thoracic oncology: a new ERJ series. European Respiratory Journal, 2014, 43, 1571-1572.	3.1	1
299	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. Journal of Thoracic Oncology, 2014, 9, 144-153.	0.5	83
300	Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1625-1633.	0.5	74
301	Synaptic Release of CCL5 Storage Vesicles Triggers CXCR4 Surface Expression Promoting CTL Migration in Response to CXCL12. Journal of Immunology, 2014, 193, 4952-4961.	0.4	12
302	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	0.6	246
303	Dendritic Cellâ€“Derived Exosomes as Immunotherapies in the Fight against Cancer. Journal of Immunology, 2014, 193, 1006-1011.	0.4	231
304	Customized Adjuvant Phase II Trial in Patients With Nonâ€“Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	0.8	66
305	Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?. Lung Cancer, 2014, 83, 383-388.	0.9	43
306	LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, e62-e63.	0.5	29

#	ARTICLE	IF	CITATIONS
307	Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience.. Journal of Clinical Oncology, 2014, 32, 11035-11035.	0.8	4
308	A phase II study of miliciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC).. Journal of Clinical Oncology, 2014, 32, 7526-7526.	0.8	11
309	Impact of tumor burden on tyrosine kinase inhibitors (TKI) efficacy in advanced non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations (EGFRm) and ALK rearrangement (ALK+).. Journal of Clinical Oncology, 2014, 32, e19021-e19021.	0.8	2
310	A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).. Journal of Clinical Oncology, 2014, 32, TPS8119-TPS8119.	0.8	3
311	National multidisciplinary tumor board (MTB): Report of the first 526 questions raised within RYTHMIC, the network for thymic malignancies in France.. Journal of Clinical Oncology, 2014, 32, 7605-7605.	0.8	0
312	Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy.. Journal of Clinical Oncology, 2014, 32, 2565-2565.	0.8	0
313	Weight, skeletal muscle mass, and adipose tissue loss during lung cancer patients' treatment.. Journal of Clinical Oncology, 2014, 32, e20627-e20627.	0.8	0
314	Abstract 2357: Gene expression profiling robustly predicts the outcome of patients diagnosed with early stage lung adenocarcinoma. , 2014, , .		0
315	Abstract 4818: Detection ofROS1rearrangement in circulating tumor cells in ROS1-positive non-small-cell lung cancer patients. , 2014, , .		0
316	Thymic carcinomas: clinicopathologic study of 37 cases from a single institution. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 307-313.	1.4	42
317	Integrated molecular portrait of non-small cell lung cancers. BMC Medical Genomics, 2013, 6, 53.	0.7	51
318	ERCC1 and RRM1: Ready for Prime Time?. Journal of Clinical Oncology, 2013, 31, 1050-1060.	0.8	73
319	Recurrence of Thymoma in the Right Atrium Arising From the Coronary Sinus. Annals of Thoracic Surgery, 2013, 95, e71-e72.	0.7	7
320	First case report of intrathecal panitumumab for treatment of meningeal carcinomatosis in an EGFR mutant lung adenocarcinoma patient. Lung Cancer, 2013, 80, 113-114.	0.9	4
321	What can be done for patients with NSCLC without druggable targets?. Lancet Oncology, The, 2013, 14, 191-192.	5.1	1
322	Crizotinib versus Chemotherapy in Advanced<i>ALK</i>-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394.	13.9	3,181
323	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-€Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1529-1537.	0.5	33
324	Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle, 2013, 12, 647-654.	1.3	16

#	ARTICLE	IF	CITATIONS
325	Detection of Circulating Tumor Cells Harboring a Unique <i>ALK</i> Rearrangement in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2273-2281.	0.8	276
326	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	0.8	572
327	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. <i>Clinical Cancer Research</i> , 2013, 19, 4315-4325.	3.2	32
328	Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials. <i>Oncology Research and Treatment</i> , 2013, 36, 357-362.	0.8	1
329	Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients. <i>Bulletin Du Cancer</i> , 2013, 100, E30-E37.	0.6	6
330	Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy.. , 2013, , .		0
331	Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1179-1183.	0.5	23
332	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. <i>Cell Reports</i> , 2012, 2, 257-269.	2.9	122
333	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	9.4	1,186
334	Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 301-313.	2.0	76
335	Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 76, 78-83.	0.9	33
336	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy. <i>Molecular Oncology</i> , 2012, 6, 204-210.	2.1	18
337	Circulating Tumor Cells in Lung Cancer. <i>Acta Cytologica</i> , 2012, 56, 655-660.	0.7	65
338	Abstract 1715: High <i>ALK</i> gene copy number as a predictor of response to crizotinib in non-small cell lung cancer cell lines. , 2012, , .		1
339	Abstract B45: Upfront genomic testing in non-small cell lung cancer (NSCLC) patients: Preliminary result of the MSN study. <i>Clinical Cancer Research</i> , 2012, 18, B45-B45.	3.2	0
340	Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 474-480.	0.9	17
341	Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. <i>Lung Cancer</i> , 2011, 74, 544-548.	0.9	1
342	Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1418-1425.	0.5	59

#	ARTICLE	IF	CITATIONS
343	Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 369-379.	2.0	43
344	Reply to A.H. Fischer et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3332-3333.	0.8	16
345	Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL. <i>Journal of Immunology</i> , 2011, 187, 5532-5539.	0.4	37
346	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. <i>Clinical Cancer Research</i> , 2011, 17, 5562-5572.	3.2	56
347	Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, e133-e138.	0.6	44
348	A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1054-1059.	0.5	84
349	Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. <i>Investigational New Drugs</i> , 2010, 28, 102-105.	1.2	1
350	Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3076-3083.	0.8	402
351	The Evolving Role of Histology in the Management of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5311-5320.	0.8	247
352	Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1527-1533.	0.8	209
353	Rhinitis in Patients Treated with a Combination of an mTOR Inhibitor and an EGFR Inhibitor. <i>Onkologie</i> , 2010, 33, 401-402.	1.1	4
354	Bevacizumab Safety in Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , 2010, 16, 269-278.	3.2	236
355	Other Molecular Targeted Agents in Non-small Cell Lung Cancer. , 2010, , 253-278.		0
356	Quantification of Circulating Vascular Endothelial Growth Factor Receptor-3-Positive Lymphatic/Vascular Endothelial Progenitor Cells. <i>Clinical Cancer Research</i> , 2009, 15, 6740-6740.	3.2	1
357	Nonseminomatous germ cell tumors: Assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2009, 137, 448-452.	0.4	60
358	QT interval prolongation among patients treated with angiogenesis inhibitors. <i>Targeted Oncology</i> , 2009, 4, 89-97.	1.7	30
359	Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1212-1220.	0.5	97
360	Hypokalemia, metabolic alkalosis, and hypertension in a lung cancer patient. <i>Kidney International</i> , 2009, 76, 115-120.	2.6	14

#	ARTICLE	IF	CITATIONS
361	Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1504-1510.	0.5	15
362	Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer. <i>Oncology</i> , 2009, 23, 520-7.	0.4	8
363	Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers. <i>Clinical Cancer Research</i> , 2008, 14, 4096-4102.	3.2	20
364	Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5014-5017.	0.8	16
365	Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 677-679.	0.5	18
366	Erythropoietin and Erythropoietin Receptor Coexpression Is Associated with Poor Survival in Stage I Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4825-4831.	3.2	36
367	Nonapoptotic Role for Apaf-1 in the DNA Damage Checkpoint. <i>Molecular Cell</i> , 2007, 28, 624-637.	4.5	116
368	Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. <i>Lung Cancer</i> , 2005, 47, 315-323.	0.9	33
369	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. <i>Lung Cancer</i> , 2005, 50, 25-33.	0.9	74
370	Nuclear Localization of Apoptosis Protease Activating Factor-1 Predicts Survival after Tumor Resection in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5665-5669.	3.2	26